<prompt> Drug of choice in stage-I hypertension with diabetic nephropathy associated with frank Proteinuria isAlpha blockerBeta blockerCalcium channel blockerACE inhibitor  <response>: D ACE inhibitor In all types of kidney disease, renin-angiotensin system RAS blockade with ACE inhibitors is superior to alternative anti- hypertensive agents if proteinuria is present. This is not the case in the absence of proteinuria. Therefore, in diabetic patients with proteinuric kidney disease, albuminuriaproteinuria are treatment targets and indications for RAS blockade. In diabetic patients, both ACE inhibitors and angiotensin receptor blockers ARBs cause BP-independent reduction of the onset of microalbuminuria. In patients with proteinuric diabetic kidney disease, baseline proteinuria predicted both renal and cardiovascular end points; furthermore, lowering of proteinuria by ARBs was associated with significant reduction in renal and cardiovascular end points. In the Irbesartan in Diabetic Nephropathy Trial IDNT, lowering proteinuria by more than 50 reduced the risk of adverse renal outcome by 50. Assignment to irbesartan resulted in a 33 reduction in risk P.001 for reaching a renal end point beyond that achieved by lowering the systolic BP. Even in patients who achieved a systolic BP 134 mm Hg, adverse renal outcomes were significantly reduced with irbesartan 12 compared with amlodipine plus placebo 20; relative risk, 0.55. Effects of lower systolic BP and treatment with irbesartan were additive and completely independent, in line with the finding that in all types of proteinuric renal disease, both BP lowering and RAS blockade have beneficial effects on outcome. 